Incidental cardiac uptake of
Amyloid heart disease
cardiomyopathy
diagnostic and prognostic application
outcomes
transthyretin amyloidosis
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
07
09
2021
accepted:
27
02
2022
pubmed:
20
4
2022
medline:
14
1
2023
entrez:
19
4
2022
Statut:
ppublish
Résumé
Bone scintigraphy (BS) is highly diagnostic for amyloid transthyretin (ATTR) cardiomyopathy. Prevalence and prognostic value of BS cardiac uptake is not well established. Our aim was to assess the prevalence of subclinical cardiac ATTR amyloidosis in patients undergoing [ BS scans performed for any clinical indications from 2009 to 2020 were reviewed. Patients were stratified according to Perugini visual score of cardiac uptake. Follow-up data were collected. Among 9616 BS scans, 0.7% (n = 67) showed cardiac uptake. In 47 (70%) patients, Perugini score was 1 and in 20 (30%) patients uptake was ≥ 2, suggesting cardiac ATTR amyloidosis. Forty subjects (61%) died during the follow-up (mean 47 ± 30 months). Compared with patients with Perugini score 1, those Perugini score ≥ 2 showed increased death rate (P = .018). Two (2/67) subjects were investigated for TTR gene mutations resulting negative. In patients undergoing BS for different clinical indications, cardiac uptake suggesting cardiac ATTR amyloidosis is a rare, but still neglected finding, thus preventing possible diagnosis of ATTR cardiomyopathy. Importantly, cardiac uptake negatively affects the survival. Physicians should be aware of this rare, but crucial finding for timely diagnosis and treatment.
Sections du résumé
BACKGROUND
Bone scintigraphy (BS) is highly diagnostic for amyloid transthyretin (ATTR) cardiomyopathy. Prevalence and prognostic value of BS cardiac uptake is not well established. Our aim was to assess the prevalence of subclinical cardiac ATTR amyloidosis in patients undergoing [
METHODS AND RESULTS
BS scans performed for any clinical indications from 2009 to 2020 were reviewed. Patients were stratified according to Perugini visual score of cardiac uptake. Follow-up data were collected. Among 9616 BS scans, 0.7% (n = 67) showed cardiac uptake. In 47 (70%) patients, Perugini score was 1 and in 20 (30%) patients uptake was ≥ 2, suggesting cardiac ATTR amyloidosis. Forty subjects (61%) died during the follow-up (mean 47 ± 30 months). Compared with patients with Perugini score 1, those Perugini score ≥ 2 showed increased death rate (P = .018). Two (2/67) subjects were investigated for TTR gene mutations resulting negative.
CONCLUSIONS
In patients undergoing BS for different clinical indications, cardiac uptake suggesting cardiac ATTR amyloidosis is a rare, but still neglected finding, thus preventing possible diagnosis of ATTR cardiomyopathy. Importantly, cardiac uptake negatively affects the survival. Physicians should be aware of this rare, but crucial finding for timely diagnosis and treatment.
Identifiants
pubmed: 35437680
doi: 10.1007/s12350-022-02961-2
pii: 10.1007/s12350-022-02961-2
doi:
Substances chimiques
Diphosphonates
0
Prealbumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3419-3425Informations de copyright
© 2022. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
Références
Adams D, Koike H, Slama M, Coelho T. Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease. Nat Rev Neurol 2019;15:387‐404.
doi: 10.1038/s41582-019-0210-4
Mankad AK, Shah KB. Transthyretin cardiac amyloidosis. Curr Cardiol Rep 2017;19:97.
doi: 10.1007/s11886-017-0911-5
Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: A comprehensive review. Arch Intern Med 2006;166:1805‐13.
doi: 10.1001/archinte.166.17.1805
Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. Circulation 2016;133:282‐90.
doi: 10.1161/CIRCULATIONAHA.115.018852
Hodkinson HM, Pomerance A. The clinical significance of senile cardiac amyloidosis: A prospective clinico-pathological study. Q J Med 1977;46:381‐7.
Cappelli F, Gallini C, Di Mario C, Costanzo EN, Vaggelli L, Tutino F. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol 2019;26:497‐504.
doi: 10.1007/s12350-017-0922-z
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Card Fail 2019;25:e1‐39.
doi: 10.1016/j.cardfail.2019.08.001
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. Expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. J Nucl Cardiol 2020;27:659‐73.
doi: 10.1007/s12350-019-01761-5
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:04‐2412.
doi: 10.1161/CIRCULATIONAHA.116.021612
Rapezzi C, Quarta CC, Guidalotti PL, Pettinato C, Fanti S, Leone O, et al. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 2011;4:659‐70.
doi: 10.1016/j.jcmg.2011.03.016
Al-Nahhas AM, Jinnouchi S, Anagnostopoulos C, Hirsch W, Heary T, McCready VR. Clinical significance of technetium-99m methylene diphosphonate myocardial uptake: Association with carcinoma of the prostate. Eur J Nucl Med 1995;22:148‐53.
doi: 10.1007/BF00838945
Bianco M, Parente A, Biolè C, Righetti C, Spirito A, Luciano A, et al. The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy. J Nucl Cardiol 2021;28:825‐30.
doi: 10.1007/s12350-021-02575-0
Longhi S, Guidalotti PL, Quarta CC, Gagliardi C, Milandri A, Lorenzini M, et al. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. JACC Cardiovasc Imaging 2014;7:531‐2.
doi: 10.1016/j.jcmg.2014.03.004
Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018;379:11‐21.
doi: 10.1056/NEJMoa1716153
Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;379:22‐31.
doi: 10.1056/NEJMoa1716793
Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007‐16.
doi: 10.1056/NEJMoa1805689
Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis: A new wave of hope after years of stagnancy? Eur J Heart Fail 2020;22:39‐53.
doi: 10.1002/ejhf.1695
Suomalainen O, Pilv J, Loimaala A, Mätzke S, Heliö T, Uusitalo V. Prognostic significance of incidental suspected transthyretin amyloidosis on routine bone scintigraphy. J Nucl Cardiol 2020;2020:1‐9.
Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicar-boxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076‐84.
doi: 10.1016/j.jacc.2005.05.073
Ben-Haim S, Chicheportiche A, Goshen E, Arad M, Smekhov M, Menezes LJ, et al. Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis. EJNMMI Res 2021;11:86.
doi: 10.1186/s13550-021-00828-0